Molecular Genetics of the Caveolin Gene Family: Implications for Human Cancers, Diabetes, Alzheimer Disease, and Muscular Dystrophy  by Engelman, Jeffrey A. et al.
Am. J. Hum. Genet. 63:1578–1587, 1998
1578
PROTEIN COMPLEXES ’98
Molecular Genetics of the Caveolin Gene Family: Implications for Human
Cancers, Diabetes, Alzheimer Disease, and Muscular Dystrophy
Jeffrey A. Engelman,1 XiaoLan Zhang,1 Ferruccio Galbiati,1 Daniela Volonte´,1 Federica Sotgia,1
Richard G. Pestell,2 Carlo Minetti,4 Philipp E. Scherer,3 Takashi Okamoto,5 and
Michael P. Lisanti1
1Department of Molecular Pharmacology and the Albert Einstein Cancer Center, 2Department of Developmental and Molecular Biology,
Department of Medicine, and the Albert Einstein Cancer Center, and 3Department of Cell Biology, Albert Einstein College of Medicine,
Bronx; 4Servizio Malattie-Neuromuscolari, University of Genoa, Gaslini Institute, Genoa; and 5Department of Neurosciences, The Lerner
Research Institute, Cleveland Clinic Foundation, Cleveland
Caveolae, the “little caves” first described in electron
micrographs of endothelial cells, have emerged, in recent
years, as the site of important dynamic and regulatory
events at the plasma membrane. Both transcytosis and
potocytosis occur within these cell-surface organelles, as
does the uptake of atherogenic oxidized LDL particles
via endothelial scavenger receptors, the uptake of chol-
era toxin and DNA tumor viruses, and the processing
of Alzheimer disease–related protein (amyloid precursor
protein [APP]) and of the scrapie prion protein (see Oka-
moto et al. 1998, and references cited within).
Caveolae are also implicated in signal transduction,
particularly by receptor tyrosine kinases (RTKs) and G-
proteins. Caveolins, a family of highly conserved integral
membrane proteins, interact specifically with these sig-
naling molecules and many of their binding partners,
apparently providing a scaffold that places members of
a signal-transduction pathway in close proximity with
one another. In many cases, interaction with caveolins
represses kinase activation, although, as we describe be-
low, such interactions can also activate signaling. Ge-
netic and biochemical findings have led us and others to
the “caveolae signaling hypothesis,” which states that
caveolar localization of certain lipid-modified signaling
molecules could provide a compartmental basis for or-
ganizing a subset of signal-transduction events (Sargia-
como et al. 1993; Lisanti et al. 1994a, 1994b). We argue
here that caveolins may provide a selective framework
that segregates one group of signaling events from the
next, preventing cross-talk between functionally unre-
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lated signaling modules while facilitating cross-talk be-
tween related signaling modules. We also review the mo-
lecular genetics of the caveolin gene family and its
implications for the pathogenesis and possible preven-
tion of four human diseases: cancer, diabetes, Alzheimer
disease, and muscular dystrophy.
Structure of Caveolae and the Caveolins
Caveolae are enriched relative to the rest of the cell
surface in specific lipids (glycosphingolipids, sphingo-
myelin, and cholesterol) and lipid-modified signaling
molecules. Because of their distinctive protein and lipid
profile, plasma-membrane caveolae are detergent insol-
uble at 4C and can be purified away from other cellular
membranes by sucrose density-gradient centrifugation.
Caveolae can also be prepared by detergent-free methods
(Smart et al. 1995), such as affinity purification using a
recombinant form of caveolin-1 (Song et al. 1996a).
These detergent-free caveolae preparations are dramat-
ically enriched in lipid-modified signaling molecules (G-
proteins, Src-tyrosine kinases, H-Ras, and endothelial-
cell nitric oxide synthase [eNOS]) (Smart et al. 1995;
Song et al. 1996a; Okamoto et al. 1998); however, gly-
cosyl-phosphatidylinositol (GPI) domains are separated
from caveolae by use of this detergent-free procedure,
as evidenced by exclusion of the GPI-anchored protein
marker—carbonic anhydrase IV (Song et al. 1996a).
Caveola-like vesicles can be generated by expression
of caveolin-1 or -3 in insect cells, by employment of a
baculovirus-based expression system, or mammalian cell
lines (Li et al. 1996b, 1998; Engelman et al. 1997). This
provides an in vivo assay for caveolin-dependent vesicle
formation. In addition, caveolin-induced vesicle for-
mation appears to be isoform specific. Expression of
caveolin-2 alone under the same conditions fails to drive
the formation of vesicles (Engelman et al. 1997; Li et
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Figure 2 Alignment of the protein sequences and functional do-
mains encoded by the last exon of murine Cav-1, -2, and -3. The
positions of the oligomerization domain (single thin overline [Sargia-
como et al. 1995]), the caveolin-scaffolding domain (double thin ov-
erline [Li et al. 1996a; Couet et al. 19971997a, 1997b, 1997c]), the
membrane-spanning domain (thick overline), and cysteines, conserved
in caveolin-1 and -3, that are sites of palmitoylation (asterisks [*]) are
shown. In addition, 10 of the 12 residues that are invariant between
all known mammalian caveolins and caveolins from C. elegans (Tang
et al. 1997) are localized to this last exon (boxes). Conserved residues
that are deleted or mutated in human caveolin-3 and that lead to an
autosomal dominant form of limb-girdle muscular dystrophy (Minetti
et al. 1998) are indicated (underlines).
Figure 1 Genomic organization of the caveolin gene family. The
overall genomic organization of the murine caveolin gene family is
shown; identical intron-exon boundaries have been reported for the
human caveolin gene family (Engelman et al. 1998c, 1998d).
al. 1998), either in insect cells or in mammalian cell
systems.
The mammalian caveolin family consists of caveolin-
1, -2, and -3 (Parton 1996; Scherer et al. 1996; Tang et
al. 1996; Okamoto et al. 1998). Caveolin-1 and -2 are
coexpressed and form a hetero-oligomeric complex
(Scherer et al. 1997) in many cell types, with particularly
high levels in adipocytes, whereas expression of caveo-
lin-3 is muscle specific and found in all classes of muscle
cells (Song et al. 1996b). This pattern of expression
should allow the development of drugs that target cav-
eolar function in specific tissues.
The genomic organization of the genes encoding cav-
eolin-1, -2, and -3 is shown schematically in figure 1.
The caveolin-1 gene contains three exons, whereas both
the caveolin-2 gene and the caveolin-3 gene each contain
only two exons (Engelman et al. 1998c, 1998d). Inter-
estingly, the boundary position of the last exon is es-
sentially identical in all three caveolin genes (Engelman
et al. 1998c, 1998d). Alignment of the protein sequences
encoded by this segment is shown in figure 2. Note that
most of the functional domains of the caveolins are con-
tained within the last exon, including the homo-oligo-
merization domain (Sargiacomo et al. 1995), the scaf-
folding domain (Li et al. 1996a; Couet et al. 1997a,
1997b, 1997c), the membrane-spanning domain, and
the C-terminal domain. This exon also encodes 10 of
the 12 invariant residues that are conserved, from worms
to man, in all members of the caveolin gene family (Tang
et al. 1997). Given that the members of the mammalian
caveolin gene family share a similar genomic organiza-
tion with a virtually identical boundary for the last exon,
it is likely that the caveolin gene family arose through
gene duplication of this last exon (Engelman et al. 1998c,
1998d).
The genes encoding murine caveolin-1 and -2 are colo-
calized within the A2 region of mouse chromosome 6
(6-A2) (see table 1 and fig. 3). Human CAV1 and CAV2
map to 7q31, in a region of conserved synteny with
murine 6-A2 (Engelman et al. 1998c, 1998d). Similarly,
the muscle-specific CAV3 gene is conserved, both at the
level of sequence and at the level of chromosomal con-
text, between mouse and man. The human CAV3 gene,
which underlies an autosomal dominant form of limb-
girdle muscular dystrophy (Minetti et al. 1998), maps
to 3p25, corresponding to the mouse region 6-E1. Cav-
eolins are also found in the nematode Caenorhabditis
elegans, suggesting that caveolae are an ancient and ev-
olutionarily conserved feature of metazoan life. The C.
elegans Cavce-1 and Cavce-2 genes are present on differ-
ent chromosomes and appear, on the basis of sequence
similarities, to correspond most closely to human CAV1
and CAV2 (table 2). These findings open the way toward
the use ofC. elegans as a genetic system to study caveolae
and caveolins (Tang et al. 1997).
The Caveolin-Scaffolding Domain
The subcellular distribution of several signaling mol-
ecules is restricted and regulated by association with
scaffolding proteins (Rubin 1994; Faux and Scott 1996).
These scaffolding proteins—Ste5p, A-kinase anchor pro-
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Figure 3 Human caveolin-1 and -2, located at the D7S522 locus
(7q31.1), a known fragile site that is frequently deleted in human
cancers. Location of the human caveolin-1 and -2 genes is shown with
respect to the markers D7S486, D7S522, and the MET proto-oncogene
(Engelman et al. 1998d). The smallest common deleted region (∼1,000
kb), as previously defined by LOH analysis, is shown. Note that
D7S522 is located at the center of this region. More specifically,
D7S522 is ∼500 kb downstream from the marker D7S486 and ∼500
kb upstream from the MET proto-oncogene. Given that the average
insert size of the caveolin containing bacterial-artificial-chromosome
genomic clones is ∼80–100 kb, the caveolin-1 and -2 genes must be
located a maximum distance of ∼100 kb upstream or downstream of
D7S522 (Engelman et al. 1998d). Thus, the position of the caveolin-
1 and -2 genes lies at the center of this smallest common deleted region
(Engelman et al. 1998d).
Table 1







MARKERS OR GENESa ASSOCIATED DISEASE REFERENCESMouse Human
Cav-1 6A2 7q31.1 3 D7S522, WI-5336, MET Cancer Engelman et al. (1998c, 1998d)
Cav-2 6A2 7q31.1 2 D7S522, WI-5336, MET Cancer Engelman et al. (1998c, 1998d)
Cav-3 6E1 3p25 2 ND Muscular dystrophy McNally et al. (1998), Minetti et al. (1998)
a D7S522 is a Ge´ne´thon CA microsatellite-repeat marker, and WI-5336 is a Whitehead Institute sequence-tagged-site marker; the GenBank
accession numbers are Z17100 and G04884, respectively. ND  not determined.
teins, and 14-3-3—simultaneously associate with dis-
tinct classes of signaling proteins to form a signaling
pathway or module.
Accumulating evidence suggests that caveolins possess
all the qualities of scaffolding proteins. Caveolins form
multivalent homo- and hetero-oligomers, and each cav-
eolin-interacting protein binds to the same cytosolic
membrane-proximal region of caveolin (Sargiacomo et
al. 1995; Li et al. 1996a). Domain-mapping studies have
revealed that the interaction of caveolin-1 with signaling
molecules is mediated via a membrane-proximal region
of caveolin, termed the “caveolin-scaffolding domain”
(residues 82–101). Through this domain, caveolin-1 in-
teracts with G-protein alpha-subunits, H-Ras, Src-family
tyrosine kinases, PKC isoforms, EGF-R, Neu, and eNOS
(Engelman et al. 1998b; reviewed in Okamoto et al.
1998). In many cases, it has been shown that mutational
activation of signaling molecules (G-proteins, H-Ras, or
Src-family kinases) prevents regulated interaction with
the caveolin-scaffolding domain. These activating mu-
tations include H-Ras (G12V) and Gas (Q227L), which
are found in human cancers, suggesting that caveolin-
mediated repression of signaling may suppress cell pro-
liferation in vivo as well as in cell culture.
The caveolin-scaffolding domain recognizes a well-
defined caveolin-binding motif that includes several cru-
cial aromatic amino acid residues (Couet et al. 1997a,
1997b, 1997c). This motif was identified by use of the
caveolin-scaffolding domain to select random peptide
ligands from phage-display libraries (Couet et al. 1997a,
1997b, 1997c). The relevance of the motif that we iden-
tified was stringently evaluated by employment of a well-
characterized caveolin-binding protein, the G-protein al-
pha-subunit, Gai2. Since the identification of the
caveolin-scaffolding domain (Li et al. 1996a) and cav-
eolin-binding sequence motifs (Couet et al. 1997a,
1997b, 1997c), these observations have been extended
to other caveolin-interacting proteins. Functional cav-
eolin-binding motifs have been deduced in both tyrosine
and serine/threonine kinases, as well as in eNOS (re-
viewed in Okamoto et al. 1998). In all cases examined,
the caveolin-binding motif is located within the enzy-
matically active catalytic domain of a given signaling
molecule. For example, in the case of tyrosine and serine/
threonine kinases, a kinase domain consists of 11 con-
served subdomains (I–XI), and the caveolin-binding mo-
tif occurs within subdomain IX (Couet et al. 1997a,
1997b, 1997c). Caveolin-binding via the scaffolding do-
main is sufficient to inhibit the enzymatic activity of
these kinases in vitro. Indeed, in many cases, a synthetic
peptide corresponding to this caveolin domain is the
most potent peptide inhibitor known for these enzymes.
Agents that mimic the interaction with caveolins are po-
tentially useful as general kinase inhibitors and, possibly,
as antitumor drugs.
Recognition of signaling molecules by the caveolins
also appears to be isoform specific. Scaffolding domains
of caveolin-1 and caveolin-3 recognize a common motif,
which does not interact with caveolin-2 (Couet et al.
1997a, 1997b, 1997c). Conversely, certain isoforms of
PKC lack a defined caveolin-binding motif and, thus, are
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Table 2













Cav-1 178 100 (100) 59 (40) Ubiquitous; Cav-1 and Cav-2 are coexpressed and are
highest in adipocytes, endothelia, epithelia, smooth
muscle cells, and type I pneumocytes
Scherer et al. (1996, 1997a)
Cav-2 162 58 (38) 100 (100)
Cav-3 159 85 (65) 60 (39) Muscle specific; primarily skeletal and cardiac myocytes Parton (1996), Song et al.
(1996b), Tang et al.
(1996)
C. elegans:
Cavce-1 235 67 (37) 65 (32) Unknown Tang et al. (1997)
Cavce-2 351 44 (24) 44 (24) Unknown Tang et al. (1997)
not inhibited by the caveolin-scaffolding domain (Oka
et al. 1997). Alanine-scanning mutagenesis of the cav-
eolin-scaffolding domain has revealed that the sequence
FTVT/S is essential for proper recognition of caveolin-
binding motifs; this sequence is conserved in caveolin-1
and -3 and is divergent in caveolin-2 (FEIS) (Couet et
al. 1997a, 1997b, 1997c). Recently, we have identified
a family with an autosomal dominant form of limb-
girdle muscular dystrophy (Minetti et al. 1998). In this
family, the FTVT/S region is deleted in caveolin-3, pro-
viding genetic evidence that this region of the caveolin-
scaffolding domain is critical in vivo.
The relevance of the caveolin-binding motif within
eNOS has recently been tested functionally (Garcia-Car-
dena et al. 1997). The caveolin-binding motif within
eNOS was removed by site-directed mutagenesis by sub-
stitution of alanine in place of important aromatic res-
idues that are required for recognition by caveolins. Re-
moval of the eNOS caveolin-binding motif did not affect
the basal enzymatic activity of eNOS, but it did block
the ability of caveolin-1 to suppress eNOS activity in
cotransfection experiments. This is the first demonstra-
tion that the caveolin-scaffolding domain and caveolin-
binding sequence motifs are functional in vivo. These
NOS-caveolin interactions have been shown to be rel-
evant in both endothelial cells and cardiac myocytes,
which express caveolin-1 and -3, respectively.
Implications for Human Genetic Diseases
Caveolins have been implicated in a variety of human
diseases. We concentrate here on four such pathologies
that have a strong hereditary component—cancer, dia-
betes mellitus, Alzheimer disease, and limb-girdle mus-
cular dystrophy. Mutations in CAV3 are now known to
lead directly to a type of limb-girdle muscular dystrophy
(fig. 4), and cell-culture or biochemical findings suggest
that heritable differences in the interaction between cav-
eolins and their partners could lead to the other con-
ditions as well, as detailed below.
Cancer: CAV1 as a Tumor-Suppressor Gene and a
Negative Regulator of the Ras-p42/44 MAP Kinase
Cascade
Modification and/or inactivation of caveolin-1 ex-
pression appears to be a common feature of the trans-
formed phenotype. Historically, caveolin was first iden-
tified as a major v-Src substrate in Rous sarcoma
virus–transformed cells (Glenney 1992). Caveolin-1
mRNA and protein expression are reduced or absent in
NIH 3T3 cells transformed by a variety of activated
oncogenes (v-Abl, Bcr-Abl, and H-Ras [G12V]), and cav-
eolae are also missing from these transformed cells (Ko-
leske et al. 1995); caveolin-2 protein is not down-reg-
ulated in response to oncogenic transformation (Scherer
et al. 1997a). In addition, caveolin-1–expression levels
correlated inversely with the ability of these cells to grow
in soft agar. Thus, cells expressing the smallest amount
of caveolin-1 and lacking detectable caveolae formed the
largest colonies in soft agar, as would be predicted if
caveolin represents a critical suppressor of cell
transformation.
Down-regulation of caveolin-1 is a direct consequence
of the oncogenic stimulus, since it can be reversed by
employing a temperature sensitive form of v-Abl or by
treating Ras-transformed 3T3 cells with an inhibitor of
the p42/44 MAP kinase pathway. Reintroduction of cav-
eolin-1 under the control of an inducible-expression sys-
tem is sufficient to block the anchorage-independent
growth of these transformed cells in soft agar and to
restore the formation of morphologically detectable cav-
eolae (Engelman et al. 1997). Consistent with its antag-
onism to Ras-mediated cell transformation, caveolin-1
expression dramatically inhibited both Ras/MAPK-me-
diated and basal transcriptional activation of a mitogen-
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Figure 4 Caveolin-3 and muscular dystrophy. Residues that are deleted or mutated in human caveolin-3 and that lead to a form of limb-
girdle muscular dystrophy are indicated (boxes) [McNally et al. 1998; Minetti et al. 1998]). Note that three of the four mutations thus far
identified cluster within the caveolin-scaffolding domain, a 20-amino-acid membrane proximal region of caveolin-3 (unbrokenunderline [McNally
et al. 1998; Minetti et al. 1998]). One mutation occurs within the transmembrane domain (dashed underline [Minetti et al. 1998]). Prefixes to
“Cav” are as follows”: m  mouse; r  rat; h  human.
sensitive promoter (Engelman et al. 1997). Taken to-
gether, these results indicate that down-regulation of
caveolin-1 expression and caveolae may be critical to
maintenance of the transformed phenotype in certain cell
populations (Engelman et al. 1997).
Human tumor cytogenetic data are consistent with
this proposal. Loss of heterozygosity (LOH) analysis im-
plicates 7q31.1 in the pathogenesis of multiple types of
cancer, including breast, ovarian, prostate, and colorec-
tal carcinomas, as well as uterine sarcomas and leiomyo-
mas. The locus of the presumed 7q31.1 tumor-suppres-
sor gene has been narrowed to an ∼1-Mb region that
includes the highly polymorphic marker D7S522. Zenk-
lusen and colleagues have shown that the D7S522 locus
is the most commonly deleted marker in primary breast
cancers, and they note that LOH at this site is strongly
associated with systemic progression and death in pros-
tate cancers (see references cited in Engelman et al.
1998c, 1998d). D7S522 also spans the aphidicolin-in-
duced fragile site FRA7G, at 7q31. Given the utility of
7q31.1 and D7S522 LOH as markers for carcinogenesis,
many laboratories are currently searching this chro-
mosomal region for a novel tumor-suppressor gene. Re-
cently, we have shown that CAV1 and CAV2 map to
!100 kb from D7S522, in the middle of the critical re-
gion for the presumed tumor-suppressor gene (fig. 3; also
see Engelman et al. 1998c, 1998d). Evidence that cav-
eolin-1 can suppress cell transformation in murine fi-
broblasts and human breast cancer cell lines provides
independent support for the model that CAV1 is the
missing tumor-suppressor gene (Engelman et al. 1997;
Lee et al. 1998b).
Interestingly, Yang et al. (1998b) recently reported
that elevated caveolin-1 levels may be associated with
prostate-cancer lymph-node metastases, raising the pos-
sibility that CAV1 could also act as an oncogene. How-
ever, because the closest known gene to CAV1 is the
MET proto-oncogene (Engelman et al. 1998d), this find-
ing may simply reflect coamplification of CAV1 along
with MET. MET was first identified and cloned as a
metastasis-associated gene (Giordano et al. 1989); mu-
tational activation or amplification of MET is known to
be associated with invasive cell growth and metastasis,
including prostate-cancer progression (Pisters et al.
1995). Alternatively, caveolin-1 expression may be up-
regulated in response to drug resistance, as has recently
been documented for the lung carcinoma–derived cell
line, A549 (Yang et al. 1998a). Finally, caveolin-1 may
be mutated in these metastatic cancer cells, a possibility
that deserves direct examination.
These findings may also have relevance for other hu-
man cancers. Using differential display and subtractive
hybridization techniques, Sager et al. (1994) have iden-
tified a number of candidate tumor-suppressor genes,
whose mRNAs are down-regulated in human mammary
carcinomas. In this screening approach, caveolin-1 was
independently identified as 1 of 26 gene products down-
regulated during mammary tumorigenesis. In addition,
caveolin-1 expression was absent in several transformed
cell lines derived from human mammary carcinomas,
including MT-1, MCF-7, ZR-75-1, T47D, MDA-MB-
361, and MDA-MB-474 (Sager et al. 1994). In contrast,
caveolin-1 mRNA was abundantly expressed in normal
mammary epithelium. However, it remains unknown
whether loss or reductions in caveolin-1 protein ex-
pression are sufficient to mediate cell transformation
and/or tumorigenicity.
Recently, we have employed an antisense approach to
derive stable NIH 3T3 cell lines that contain normal
amounts of caveolin-2 but express dramatically reduced
levels of caveolin-1 (Galbiati et al. 1998a). NIH 3T3
cells harboring antisense caveolin-1 spontaneously
formed foci, exhibited anchorage-independent growth in
soft agar, formed tumors in immunodeficient mice, and
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appeared morphologically transformed as seen by scan-
ning electron microscopy (Galbiati et al. 1998a). Bio-
chemically, these cells also showed increased levels of
activated MEK and ERK (Galbiati et al. 1998a). How-
ever, the SAPK/JNK pathway, the p38 MAPK pathway,
and CREB were not activated in these cells. Taken to-
gether, these results suggest that down-regulation of cav-
eolin-1 expression is sufficient to drive oncogenic trans-
formation and to constitutively activate the p42/44 MAP
kinase cascade (Galbiati et al. 1998a). Importantly, cell
transformation induced by targeted down-regulation of
caveolin-1 expression was completely reversed when
caveolin-1 protein levels were restored to normal by loss
of the caveolin-1 antisense vector (Galbiati et al. 1998a).
Several laboratories have now shown, by both in vitro
biochemical methods and in vivo immunolabeling tech-
niques, that components of the p42/44 MAP kinase cas-
cade, MEK and ERK, are concentrated within caveolar
membranes (Song et al. 1996a; Liu et al. 1997a, 1997b).
For example, morphological studies have directly shown
that ERK-1/2 is concentrated in plasma-membrane cav-
eolae (Liu et al. 1997b).
How might the down-regulation of caveolin-1 protein
expression activate the p42/44 MAP kinase cascade? Re-
cently, Anderson and colleagues have shown that the
pool of ERK-1 that localizes to caveolae is initially in-
active and can be activated by regulated stimulation with
growth-factor ligands, such as PDGF (Liu et al. 1997b).
After such stimulation, ERK-1 is activated and trans-
locates from the caveolar membrane to the cytosol, sug-
gesting that ERK-1 is activated as it leaves the caveolar
membrane (Liu et al. 1997b). These results are consistent
with our current findings that down-regulation of cav-
eolin-1 expression constitutively activates signaling from
MEK and ERK in vivo, perhaps by prematurely releasing
activated ERK-1/2 and other components of the p42/44
MAP kinase cascade into the cytosol. In support of this
hypothesis, we have shown that transient coexpression
of caveolin-1 with activated H-Ras (G12V) blocks its
ability to transcriptionally activate a mitogen-sensitive
promoter in vivo (Engelman et al. 1997). Because the
G12V mutation of H-Ras prevents or destabilizes its
interaction with caveolin-1 (Song et al. 1996a), over-
expression of caveolin-1 is unlikely to influence Ras di-
rectly in this assay; rather, the activity of one or more
of the downstream targets of H-Ras, such as Raf-1,
MEK-1/2, or ERK-1/2, is probably inhibited.
In accordance with this idea, we have recently shown
that (i) transient coexpression with caveolin-1 dramat-
ically inhibits signaling from Raf-1, MEK-1, and ERK-
2 to the nuclear-transcription factor Elk in vivo and (ii)
peptides derived from caveolin-1 inhibit the in vitro ki-
nase activity of purified MEK-1 and ERK-2 (Engelman
et al. 1998a). Thus, overexpression of caveolin-1 can
inhibit signal transduction from the p42/44 MAP kinase
cascade, via a direct interaction of caveolin-1 with MEK
and ERK (Engelman et al. 1998a), whereas targeted
down-regulation of caveolin-1 is sufficient to activate the
p42/44 MAP kinase cascade constitutively (Galbiati et
al. 1998a).
On the basis of our current and previous observations,
we suggest that a novel form of negative reciprocal reg-
ulation exists between p42/44 MAP kinase activation
and caveolin-1 protein expression. The evidence is as
follows:
1. up-regulation of caveolin-1 protein expression
down-regulates p42/44 MAP kinase activity (Engelman
et al. 1998a)—that is, transient coexpression of caveolin-
1 with MEK or ERK inhibits their ability to transcrip-
tionally activate an in vivo Elk-luciferase reporter system
in CHO cells;
2. down-regulation of caveolin-1 protein expression
up-regulates p42/44 MAP kinase activity (Galbiati et al.
1998a)—that is, expression of caveolin-1 antisense
down-regulates caveolin-1 protein expression in NIH
3T3 cells and leads to constitutive activation of MEK
and ERK;
3. up-regulation p42/44 MAP kinase activity down-
regulates caveolin-1 mRNA and protein expression (Ko-
leske et al. 1995; Engelman et al. 1997)—that is, ex-
pression of activated Ras (G12V) in NIH 3T3 cells leads
to a loss of caveolin-1 mRNA and protein expression;
4. down-regulation of p42/44MAP kinase activity up-
regulates caveolin-1 protein expression (Engelman et al.
1997)—that is, treatment of Ras-transformed NIH 3T3
cells with a MEK inhibitor restores the expression of
caveolin-1 protein to normal levels observed in non-
transformed NIH 3T3 cells.
Importantly, these four independent observations are
consistent with the changes–in response to cell density,
growth-factor deprivation, and growth-factor stimula-
tion—that we observed in caveolin-1 protein levels in
normal NIH 3T3 cells (Galbiati et al. 1998a).
Diabetes: Caveolae, Caveolins, and Insulin Signaling
Signal transduction by the insulin receptor—and by
its downstream interacting partners such as IRS-1—is
important for understanding the basic mechanism of glu-
cose uptake in muscle and adipose tissue, as well as the
pathogenesis of human metabolic diseases, most notably
diabetes. In adipocytes, the cell type that expresses the
highest level of CAV1, caveolae represent as much as
20% of the total plasma-membrane surface area. Both
caveolae and caveolin-1 are induced 10–25 fold during
the differentiation of 3T3-L1 preadipocytes into mature
adipocytes (Scherer et al. 1994). Previous studies have
localized the ligand-bound insulin receptor to plasma-
membrane caveolae by electron microscopy (see refer-
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ences cited in Scherer et al. 1994). This finding raises
the question of whether caveolin-1 binding inhibits the
activity of insulin RTKs, as it inhibits other RTKs, such
as EGF-R and Neu (Couet et al. 1997c; Engelman et al.
1998b).
The caveolae-signaling hypothesis predicts that cav-
eolin-1 will not necessarily inhibit all signaling but,
rather, that it will confer differential activation and re-
pression of distinct signaling cascades. In collaboration
with Ishikawa and colleagues, we have recently found
that cotransfection of caveolin-1 with the insulin recep-
tor can stimulate the phosphorylation of IRS-1 in vivo
(Yamamoto et al. 1998). In addition, peptides encoding
the scaffolding domain of caveolin-1 dramatically stim-
ulate the ability of the insulin-receptor kinase to phos-
phorylate IRS-1 in vitro (Yamamoto et al. 1998). The
latter experiments employed only purified recombinant
insulin-receptor kinase and its substrate, purified recom-
binant IRS-1, suggesting that stimulation occurs through
a direct interaction with caveolin-1. Similar stimulatory
effects were observed with caveolin-3 that is expressed
predominantly in muscle cells. Thus, caveolins may dem-
onstrate either inhibitory or stimulatory functions, in the
context of different signal-transduction cascades.
This observation may provide the key to understand-
ing how the proliferative effects of the insulin receptor
are squelched in adipocytes; for example, caveolin-1 ex-
pression in adipocytes would promote insulin signaling,
and, at the same time, it would, by inhibiting the p42/
44 MAP kinase cascade, down-regulate mitogenic sig-
naling. This is consistent with the finding that caveolins
are most abundantly expressed in insulin-sensitive tis-
sues: fat (caveolin-1 and -2) and skeletal muscle (cav-
eolin-3) (Scherer et al. 1994, 1997a; Tang et al. 1996).
Alzheimer Disease: Caveolae, Caveolins, and APP
degradation
APP is a source of Ab amyloid peptide, the principal
protein component of the senile plaques found in the
brains of patients with Alzheimer disease. The Ab am-
yloid peptide is generated by the processing of APP with
b- and g-secretases. Alternatively, APP is processed by
a-secretase, which cleaves APP within the Ab sequence,
thereby precluding the formation of Ab. The competi-
tion between these alternative proteolytic pathways is
thus crucial to the etiology of Alzheimer disease.
Our recent evidence shows the enrichment of APP in
caveolae, where caveolin provides a direct means for
APP to be concentrated (Ikezu et al. 1998a). Interest-
ingly, the a-secretase cleavage event also occurred in cav-
eolae, and overexpression of recombinant caveolin-1–
promoted a-secretase–mediated proteolysis of APP. Con-
versely, a-secretase–mediated cleavage of APP was abol-
ished by caveolin-1–based antisense oligonucleotides
that effectively block caveolin-1 expression (Ikezu et al.
1998a). In the brain, caveolae-like microdomains of the
plasma membrane that have a similar lipid composition
have been termed “detergent- insoluble glycolipid
membrane complexes” (DIGs), or “caveolae-related do-
mains” (CRDs [Okamoto et al. 1998]). CRDs isolated
from whole brain contain not only APP but also the Ab
amyloid peptide (Lee et al. 1998a); therefore, it has been
suggested that brain CRDs represent sites of amyloid
biogenesis or transport. In support of this notion, cho-
lesterol depletion, which leads to the loss of CRD in-
tegrity, efficiently inhibits Ab amyloid–peptide secretion
in cultured hippocampal neurons (Simons et al. 1998).
Since recent studies have provided direct evidence that
caveolins are also expressed within cells of the nervous
system, including astrocytes (Ikezu et al. 1998b) and
neurons (Galbiati et al. 1998b), it is possible that cav-
eolins play a key role in APP processing in brain.
Muscular Dystrophy: Caveolin-3 and the Dystrophin
Complex
The expression of caveolin-3 is induced during the
differentiation of skeletal myoblasts, and caveolin-3 is
localized to the sarcolemma, where it forms a complex
with dystrophin and its associated glycoproteins (Song
et al. 1996b). PFK represents the rate-limiting enzyme
in glycolysis, and its muscle-specific isoform, PFK-M, is
a prominent caveolin-3–binding protein. This interac-
tion is modulated by the availability of extracellular glu-
cose and by intracellular allosteric effectors of PFK
(Scherer and Lisanti 1997), suggesting that regulation of
glycolysis by caveolin-3 could be important in patho-
genic states of skeletal muscle, such as muscular
dystrophies.
In support of this notion, we have recently identified
an autosomal dominant form of limb-girdle muscular
dystrophy (i.e., type LGMD1C) in two Italian families
that is due to a deficiency in caveolin-3 expression. Anal-
ysis of their genomic DNA reveals two distinct mutations
in CAV3: (i) a 9-bp microdeletion that removes the se-
quence TFT from the caveolin-scaffolding domain and
(2) a missense mutation that changes a proline to a leu-
cine (PrL) in the transmembrane domain (Minetti et al.
1998) (fig. 4). Both mutations lead to a loss of 195%
of caveolin-3 protein expression.
The evident loss, in cells of heterozygous individuals,
of both wild-type and mutant caveolin-3 may reflect the
targeting of mixed caveolin-3 oligomers to a degradative
pathway, but the mechanism of this process has not been
explored. However, the identity of the CAV3 lesions in
these LGMD1C families is instructive. Of the 12 amino
acid residues that are shared among all three human
caveolins as well as between the two C. elegans homo-
logues, two are affected by the mutations identified in
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these two LGMD1C families. One of the invariant pro-
lines is changed to leucine in family A, whereas one of
the invariant phenylalanines is deleted in family B (Mi-
netti et al. 1998). These results suggest that mutation of
these evolutionarily conserved residues may have dire
consequences for the structure or function of the other
caveolin-family members as well. Indeed, alanine-scan-
ning mutagenesis of a peptide encoding the caveolin-
scaffolding domain reveals that the FTVT/S sequence in
caveolin-1 and -3 is important for the correct recognition
of caveolin-binding signaling molecules (Couet et al.
1997a), and the FT residues in this sequence are deleted
in family B. Two other mutations within the coding se-
quence of CAV3 have been described that are associated
with a proximal form of muscular dystrophy (McNally
et al. 1998). One of these mutations was homozygous,
suggesting a possible autosomal recessive inheritance
(McNally et al. 1998). Interestingly, these two additional
mutations map to the caveolin-3–scaffolding domain.
Thus, the mutations in three of the four known CAV3
disease alleles cluster within the 20-amino-acid caveolin-
scaffolding domain.
Future Prospects
Caveolins share with other scaffolding factors the abil-
ity to bind multiple components of a signaling pathway.
The existence of such factors clearly affords the cell
tighter control of the activation and repression of sig-
naling than would be possible if all players diffused
freely throughout the cytoplasm. Scaffolds also allow
for integration of signal-transduction pathways into dis-
crete modules, so that they reduce the likelihood of in-
discriminate cross-talk among distinct pathways. The
significance of interactions between caveolins and their
partners is now well established in cell-culture models,
and their physiological importance is beginning to
emerge from the study of various human diseases. Her-
itable defects in CAV3 are now implicated in at least
one form of muscular dystrophy, and other lesions in
the genes for either caveolins or other scaffolds will
probably be found in cancer and in other human genetic
disorders. A novel class of disease mutations may now
come to light, in which the root cause of the disorder is
the failure of a regulatory protein to interact properly
with scaffolding factors.
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